Previously, we reported that Cyp1b1 gene disruption or chemical inhibition of CYP1B1 activity minimized the Ang II-induced increase in vascular reactivity to vasoconstrictor agents, increased vascular ROS production, and endothelial dysfunction [11]. The gene discussed is AGT; the disease is endothelial dysfunction.